Abbott Laboratories

• Danaher reaffirmed its third-quarter and full-year financial guidance. • Julie Sawyer Montgomery will assume the CEO role on October 1. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• Intuitive Surgical exceeded quarterly expectations, raising full-year guidance on high global procedure volumes. • Strong Da Vinci 5 platform adoption and recurring revenue streams drove institutional investor confidence. • Technical indicators show a sell signal, despite positive fundamental growth and market positioning.

• Stryker stock fell due to concerns regarding orthopedic demand and hospital capital spending. • Elevated treasury yields are compressing valuation multiples for high-growth medical technology firms. • Technical breaches of support levels and institutional profit-taking contributed to intraday price volatility.

• Intuitive Surgical shares declined after missing second-quarter revenue and procedure volume expectations. • Management lowered 2026 procedure growth guidance due to slowing international elective surgery rates. • Increased R&D spending and rising costs compressed operating margins, triggering institutional selling.

• Abbott Laboratories reported second-quarter earnings exceeding Wall Street expectations. • Management raised full-year earnings guidance due to strong organic sales growth. • Medical devices and nutrition segments drove overall financial performance and revenue growth.

• UnitedHealth’s second-quarter earnings beat Wall Street expectations on revenue and profit. • Management raised full-year earnings guidance, driving positive institutional investor sentiment and market rallies. • Disciplined Medical Care Ratio management mitigated investor concerns regarding rising healthcare utilization rates.